Cargando…
Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials
INTRODUCTION: Metformin is the first choice drug in the treatment of type 2 diabetes mellitus but its administration may be linked to gastrointestinal adverse events limiting its use. OBJECTIVES: The objective of this systematic review and meta-analysis was to assess the risk of gastrointestinal adv...
Autores principales: | Nabrdalik, Katarzyna, Skonieczna-Żydecka, Karolina, Irlik, Krzysztof, Hendel, Mirela, Kwiendacz, Hanna, Łoniewski, Igor, Januszkiewicz, Kornelia, Gumprecht, Janusz, Lip, Gregory Y. H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524196/ https://www.ncbi.nlm.nih.gov/pubmed/36187122 http://dx.doi.org/10.3389/fendo.2022.975912 |
Ejemplares similares
-
Machine learning identification of risk factors for heart failure in patients with diabetes mellitus with metabolic dysfunction associated steatotic liver disease (MASLD): the Silesia Diabetes-Heart Project
por: Nabrdalik, Katarzyna, et al.
Publicado: (2023) -
Low Quantitative Blush Evaluator score predicts larger infarct size and reduced left ventricular systolic function in patients with STEMI regardless of diabetes status
por: Nabrdalik, Katarzyna, et al.
Publicado: (2023) -
Machine learning profiles of cardiovascular risk in patients with diabetes mellitus: the Silesia Diabetes-Heart Project
por: Kwiendacz, Hanna, et al.
Publicado: (2023) -
Influence of SGLT2 Inhibitor Treatment on Urine Antioxidant Status in Type 2 Diabetic Patients: A Pilot Study
por: Nabrdalik-Leśniak, Diana, et al.
Publicado: (2021) -
Risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease: a machine learning approach
por: Drożdż, Karolina, et al.
Publicado: (2022)